AlloVir, Inc. (ALVR) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- ...
As of April 24, 2023, the average one-year price target for AlloVir is 22.44. The forecasts range from a low of 16.16 to a high of $31.50. The average price target represents an increase of 544.83% ...
AlloVir, Inc. (ALVR) is a good speculative biotech play to look into. The reason why I state that is because it has a great late-stage program, whereby it is advancing posoleucel for the treatment and ...
AlloVir, Inc. has some solid data in an area of unmet need. AlloVir is well-capitalized to complete its trials. However, the market doesn't seem interested at present. We're about to raise prices at ...
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of AlloVir, Inc. ...
AlloVir will discontinue its three global Phase 3 posoleucel studies as those are unlikely to meet primary endpoint. No safety concerns were observed or raised by any of the independent Data Safety ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback